Figure 6.

Relative antineoplastic cytotoxic potency of gemcitabine‐(5′‐phosphoramidate)‐[anti‐IGF‐1R] against chemotherapeutic‐resistant pulmonary adenocarcinoma. Legends: (▲) gemcitabine‐(5′‐phosphoramidate)‐[anti‐IGF‐1R]; (●) gemcitabine chemotherapeutic; and (■) monoclonal anti‐IGF‐1R IgG immunoglobulin formatted at matched standardized concentrations. Analyses of gemcitabine‐(5′‐phosphoramidate)‐[anti‐IGF‐1R] and gemcitabine were performed in triplicate at gradient standardized (gemcitabine‐equivalent) concentrations. Gemcitabine‐(5′‐phosphoramidate)‐[anti‐IGF‐1R] and gemcitabine were bother separately incubated in direct contact with monolayer populations of chemotherapeutic‐resistant pulmonary adenocarcinoma (A549) for a period of 192 h. Antineoplastic cytotoxic potency was measured using a MTT cell vitality assay relative to matched negative reference controls